Kimmtrak

Chemical Nametebentafusp-tebn
Dosage FormInjection (subcutaneous; 100 mcg/0.5 mL)
Drug ClassPeptides
SystemOcular
CompanyImmunocore
Approval Year2022

Indication

  • For the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
Last updated on 2/11/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kimmtrak (tebentafusp-tebn) Prescribing Information.2022Immunocore Limited, Abingdon, Oxfordshire
Document TitleYearSource
Overall survival benefit with tebentafusp in metastatic uveal melanoma. 2021The New England Journal of Medicine